Related references
Note: Only part of the references are listed.Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
Andrea R. Hagemann et al.
GYNECOLOGIC ONCOLOGY (2013)
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer
Colm Farrell et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Nitzan Gonen et al.
DRUG RESISTANCE UPDATES (2012)
Clinical translation of folate receptor-targeted therapeutics
Lesheng Teng et al.
EXPERT OPINION ON DRUG DELIVERY (2012)
EC145: a novel targeted agent for adenocarcinoma of the lung
Pamela Pribble et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
Patricia M. LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung
Martin J. Edelman et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer
R. Wendel Naumann et al.
DRUGS (2011)
Farletuzumab in epithelial ovarian carcinoma
Whitney A. Spannuth et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
David S. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Pharmacokinetics and Exposure-Toxicity Relationship of a Folate-Vinca Alkaloid Conjugate EC145 in Cancer Patients
Jing Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Preclinical evaluation of EC145, a folate-Vinca alkaloid conjugate
Joseph A. Reddy et al.
CANCER RESEARCH (2007)
Human reduced folate carrier: translation of basic biology to cancer etiology and therapy
Larry H. Matherly et al.
CANCER AND METASTASIS REVIEWS (2007)
A step further in understanding the biology of the folate receptor in ovarian carcinoma
M Bagnoli et al.
GYNECOLOGIC ONCOLOGY (2003)
Share Paper
